Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer

Rheumatology (Oxford). 2016 Nov;55(11):2087-2089. doi: 10.1093/rheumatology/kew281. Epub 2016 Jul 19.

Authors

Sarah Law-Ping-Man¹, Antoine Martin², Eric Briens³, Laurent Tisseau⁴, Gilles Safa⁵

Affiliations

¹ Department of Dermatology.
² Department of Rheumatology.
³ Department of Pulmonary Medicine, Centre Hospitalier de Saint-Brieuc, Saint-Brieuc, France.
⁴ Armor Pathology Laboratory, Plérin, France.
⁵ Department of Dermatology gilles.safa@ch-stbrieuc.fr.

PMID: 27436004
DOI: 10.1093/rheumatology/kew281

No abstract available

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Arthritis, Psoriatic / chemically induced*
Arthritis, Psoriatic / diagnosis
Carcinoma, Non-Small-Cell Lung / diagnosis
Carcinoma, Non-Small-Cell Lung / drug therapy*
Dose-Response Relationship, Drug
Humans
Lung Neoplasms / diagnosis
Lung Neoplasms / drug therapy*
Male
Neoplasm Staging*
Nivolumab
Psoriasis / chemically induced*
Psoriasis / diagnosis

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Nivolumab